Generic name | Serious infections | Malignancies | Autoimmune diseasea | Antibody formation |
---|---|---|---|---|
Normal childhood population | 1.0 [17] | 0.0069 new onset uveitis [77] | - | |
 |  |  | 0.0083 IBD [78] |  |
 |  |  | 0.00015 optic neuritis [79] |  |
 |  |  | 0,0001 multiple sclerosis [80] |  |
JIA without MTX, steroids or anti-TNF | 2.2 [17] | - | ||
JIA with MTX | 3.3 [17] | 0.83 uveitis [83] | - | |
JIA with steroids | 6.9 [17] | No data | No data | - |
Abatacept | 1.3 [57] | No data | 0.22 uveitis flare (1 per 448 EY) [19] | 23 (no adverse events) [57] |
 |  |  | 0.22 multiple sclerosis (1 per 448 EY) [19] |  |
Adalimumab | No data | 7.6 with MTX within year; 15 after first year (no adverse events) [28, 30] | ||
 |  |  |  | 25.3 without MTX within first year; 60 after first year (no adverse events) [28, 30] |
Anakinra | No data | No data | 75.0 non-neutralizing antibodies within first year; 81.8 after first year [73] | |
 |  |  |  | 6.3 neutralizing antibodies within first year; 0 after first year [73] |
Etanercept | 0.015 [59] | 0.44 new onset uveitis [32, 34] and 0.57 flares of uveitis [33, 35] | 2.9 non-neutralizing antibodies [74] | |
 |  |  |  | |
 |  |  |  | |
 |  |  |  | |
 |  |  | 0.64 newly diagnosed sarcoidosis [32] |  |
Infliximab | No data | 5.1 new onset uveitis [36] | 36.6 positive and 32.4 inconclusive (infusion-reaction-related) [36] | |
 |  |  | 25.9 new ANA (≥1:320) without symptoms [36] |  |
 |  |  | 6.6 new anti-double-stranded DNA antibodies without symptoms [36] |  |
Rituximab | 14.5d [24] | No data | No data | No data |
Tocilizumab | No data | No data | 7.1 (one anaphylactoid reaction without anti-IgE antibody) [38] |